Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Licochalcone A and Paclitaxel in OSCC Cell Lines
NCT03292822Phase 1Completed
- Sponsor
- Cairo University
- Start
- Feb 2021
- Primary completion
- Jan 2023
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1 trial of Licochalcone A in oral squamous cell carcinoma (OSCC) (2 arms), sponsored by Cairo University. Primary endpoint: Apoptosis at 3 days. Started Feb 2021; status: completed.
02
Drugs
Licochalcone A
03
Conditions
oral squamous cell carcinoma (OSCC)
Beyond the preview
Go deeper on NCT03292822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03292822.